Literature DB >> 15015582

Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.

Gjermund Henriksen1, Oyvind S Bruland, Roy H Larsen.   

Abstract

The present study explores the use of alpha-particle-emitting, bone-seeking agents as candidates for targeted radiotherapy. Actinium and thorium 1,4,7,10 tetraazacyclododecane N,N',N'',N''' 1,4,7,10-tetra(methylene) phosphonic acid (DOTMP) and thorium-diethylene triamine N,N',N'' penta(methylene) phosphonic acid (DTMP) were prepared and their biodistribution evaluated in conventional Balb/C mice at four hours after injection. All three bone-seeking agents showed a high uptake in bone and a low uptake in soft tissues. Among the soft tissue organs, only kidney had a relatively high uptake. The femur/kidney ratios for 227Th-DTMP, 228-Ac-DOTMP and 227Th-DOTMP were 14.2, 7.6 and 6.0, respectively. A higher liver uptake of 228Ac-DOTMP was seen than for 227Th-DTMP and 227Th-DOTMP. This suggests that some demetallation of the 228Ac-DOTMP complex had occurred. The results indicate that 225Ac-DOTMP, 227Th-DOTMP and 227Th-DTMP have promising properties as potential therapeutic bone-seeking agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015582

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

Review 2.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

3.  Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions.

Authors:  Valerie Carroll; Dustin W Demoin; Timothy J Hoffman; Silvia S Jurisson
Journal:  Radiochim Acta       Date:  2012-08       Impact factor: 1.440

4.  Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.

Authors:  Jostein Dahle; Thora J Jonasdottir; Helen Heyerdahl; Jahn M Nesland; Jørgen Borrebaek; Anne Kristine Hjelmerud; Roy H Larsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 5.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

6.  Theoretical Study of Actinide(III)-DOTA Complexes.

Authors:  Attila Kovács
Journal:  ACS Omega       Date:  2021-05-11

7.  Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.

Authors:  Nasir Abbas; Helen Heyerdahl; Oyvind S Bruland; Jørgen Borrebæk; Jahn Nesland; Jostein Dahle
Journal:  EJNMMI Res       Date:  2011-08-24       Impact factor: 3.138

8.  Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review.

Authors:  Hua Yang; Justin J Wilson; Chris Orvig; Yawen Li; D Scott Wilbur; Caterina F Ramogida; Valery Radchenko; Paul Schaffer
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 11.082

Review 9.  Development of Targeted Alpha Particle Therapy for Solid Tumors.

Authors:  Narges K Tafreshi; Michael L Doligalski; Christopher J Tichacek; Darpan N Pandya; Mikalai M Budzevich; Ghassan El-Haddad; Nikhil I Khushalani; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

Review 10.  Radionuclide carriers for targeting of cancer.

Authors:  Stavroula Sofou
Journal:  Int J Nanomedicine       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.